Quanterix (NASDAQ:QTRX – Free Report) had its target price reduced by Canaccord Genuity Group from $20.00 to $15.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.
Quanterix Trading Down 1.8 %
Shares of NASDAQ:QTRX opened at $7.15 on Tuesday. Quanterix has a 12-month low of $6.30 and a 12-month high of $27.37. The company has a fifty day simple moving average of $8.41 and a 200 day simple moving average of $10.93. The firm has a market cap of $275.45 million, a PE ratio of -6.75 and a beta of 1.34.
Quanterix (NASDAQ:QTRX – Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The firm had revenue of $35.16 million for the quarter, compared to analysts’ expectations of $34.93 million. As a group, equities research analysts forecast that Quanterix will post -0.98 EPS for the current fiscal year.
Institutional Investors Weigh In On Quanterix
About Quanterix
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Further Reading
- Five stocks we like better than Quanterix
- Short Selling: How to Short a Stock
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Why is the Ex-Dividend Date Significant to Investors?
- 3 Must-Own Stocks to Build Wealth This Decade
- NYSE Stocks Give Investors a Variety of Quality Options
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.